Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer (SUPPRESS)
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer: A Phase II Randomized Trial
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Listed as NCT04989725, this PHASE2 trial focuses on Head and Neck Cancer and Metastatic Cancer and remains actively recruiting participants. Sponsored by Centre hospitalier de l'Université de Montréal (CHUM), it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Apr 2022 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre hospitalier de l'Université de Montréal (CHUM)
For direct contact, visit the study record on ClinicalTrials.gov .